Can Lupin Sustain Its Strong Growth After A 42% Surge In Q1 EBITDA?
LUPIN Q1 FY27 RESULTS: STRONG & POSITIVE
Lupin delivered a strong Q1 FY27 performance, with robust growth across revenue, EBITDA and net profit on a year-on-year basis.
Revenue jumped 32% YoY to ₹8,277 crore, while EBITDA grew even faster at 42% YoY to ₹2,450 crore. Net profit increased 16% YoY to ₹1,417 crore.
The geographic performance was particularly impressive. The U.S., Other Developed Markets and Emerging Markets all recorded very strong double-digit growth, while the India business also maintained healthy momentum.
However, there is one important monitorable: EBITDA margin declined sequentially to 29.6% from 33.2%, despite revenue growing 11% QoQ.
Lupin delivered a strong Q1 FY27 performance, with robust growth across revenue, EBITDA and net profit on a year-on-year basis.
Revenue jumped 32% YoY to ₹8,277 crore, while EBITDA grew even faster at 42% YoY to ₹2,450 crore. Net profit increased 16% YoY to ₹1,417 crore.
The geographic performance was particularly impressive. The U.S., Other Developed Markets and Emerging Markets all recorded very strong double-digit growth, while the India business also maintained healthy momentum.
However, there is one important monitorable: EBITDA margin declined sequentially to 29.6% from 33.2%, despite revenue growing 11% QoQ.
REVENUE: ₹8,277 CR ▲ 32% YoY
EBITDA: ₹2,450 CR ▲ 42% YoY
PAT: ₹1,417 CR ▲ 16% YoY
EBITDA MARGIN: 29.6%
EBITDA: ₹2,450 CR ▲ 42% YoY
PAT: ₹1,417 CR ▲ 16% YoY
EBITDA MARGIN: 29.6%
How Did Lupin Perform In Q1 FY27?
| Metric | Q1 FY27 | YoY | QoQ |
| Net Profit | ₹1,417 Cr | 🟢 +16% | 🔴 -4% |
| Revenue | ₹8,277 Cr | 🟢 +32% | 🟢 +11% |
| EBITDA | ₹2,450 Cr | 🟢 +42% | 🔴 -1% |
| EBITDA Margin | 29.6% | 27.6% earlier | 33.2% earlier |
Revenue Growth Of 32% Sets A Strong Foundation
Lupin reported revenue of ₹8,277 crore in Q1 FY27, representing substantial growth of 32% over the corresponding period of the previous year.
Revenue also increased 11% sequentially, indicating that the company's topline growth was not restricted to a favourable year-on-year comparison.
Q1 FY27 REVENUE
₹8,277 CRORE
🟢 +32% YoY
🟢 +11% QoQ
₹8,277 CRORE
🟢 +32% YoY
🟢 +11% QoQ
The segment data indicates that this growth was broad-based rather than dependent on only one geographic market.
EBITDA Growth Of 42% Is A Major Positive
Lupin's operating profit performance was even stronger than its revenue growth.
EBITDA increased to:
This represents an impressive 42% YoY increase.
The fact that EBITDA grew considerably faster than the 32% increase in revenue indicates stronger year-on-year operating profitability.
This is also visible in the EBITDA margin, which improved to 29.6% from 27.6% YoY.
EBITDA increased to:
₹2,450 CRORE
This represents an impressive 42% YoY increase.
The fact that EBITDA grew considerably faster than the 32% increase in revenue indicates stronger year-on-year operating profitability.
This is also visible in the EBITDA margin, which improved to 29.6% from 27.6% YoY.
EBITDA Margin Expanded 200 Basis Points YoY
Lupin reported an EBITDA margin of:
compared with:
27.6% in the corresponding quarter last year.
That represents approximately 200 basis points of year-on-year margin expansion.
The combination of 32% revenue growth, 42% EBITDA growth and a 200-basis-point YoY margin improvement makes the operating performance one of the strongest features of the quarter.
29.6%
compared with:
27.6% in the corresponding quarter last year.
That represents approximately 200 basis points of year-on-year margin expansion.
The combination of 32% revenue growth, 42% EBITDA growth and a 200-basis-point YoY margin improvement makes the operating performance one of the strongest features of the quarter.
Why Does The Sequential Margin Decline Need Attention?
Despite the excellent year-on-year performance, the sequential comparison presents a different picture.
EBITDA margin declined from:
At the same time:
Revenue increased 11% QoQ
but
EBITDA declined 1% QoQ
and
PAT declined 4% QoQ.
This sequential divergence deserves attention because the substantial increase in revenue did not translate into corresponding sequential growth in operating profit or net profit.
The supplied data does not establish the precise reasons for this margin movement, so those reasons should not be assumed without examining detailed financial statements and management commentary.
EBITDA margin declined from:
33.2% → 29.6%
▼ 360 basis points QoQ
▼ 360 basis points QoQ
At the same time:
Revenue increased 11% QoQ
but
EBITDA declined 1% QoQ
and
PAT declined 4% QoQ.
This sequential divergence deserves attention because the substantial increase in revenue did not translate into corresponding sequential growth in operating profit or net profit.
The supplied data does not establish the precise reasons for this margin movement, so those reasons should not be assumed without examining detailed financial statements and management commentary.
U.S. Business Emerges As A Major Growth Engine
Lupin's U.S. business delivered particularly strong growth.
🟢 Growth: 42.9% YoY
🟢 Contribution: 42% of total sales
With the U.S. accounting for approximately 42% of total sales in the supplied segment data, its performance is particularly significant for Lupin's overall earnings trajectory.
Growth of 42.9% YoY makes the U.S. one of the most important contributors to the company's Q1 FY27 expansion.
U.S. REVENUE: ₹3,435 CRORE
🟢 Growth: 42.9% YoY
🟢 Contribution: 42% of total sales
With the U.S. accounting for approximately 42% of total sales in the supplied segment data, its performance is particularly significant for Lupin's overall earnings trajectory.
Growth of 42.9% YoY makes the U.S. one of the most important contributors to the company's Q1 FY27 expansion.
India Business Maintains Healthy Growth
Lupin's India business reported revenue of:
This represents 13.9% YoY growth and approximately 29% of total sales based on the supplied figures.
While India's growth rate was lower than the U.S. and several international markets, double-digit expansion in the domestic business adds diversification to the overall growth profile.
₹2,380 CRORE
This represents 13.9% YoY growth and approximately 29% of total sales based on the supplied figures.
While India's growth rate was lower than the U.S. and several international markets, double-digit expansion in the domestic business adds diversification to the overall growth profile.
Other Developed Markets Grow Nearly 48%
Other Developed Markets were another standout performer.
Revenue: ₹1,149 crore
Growth: 🟢 48.3% YoY
This represents one of the fastest-growing components of Lupin's geographic portfolio during the quarter.
Revenue: ₹1,149 crore
Growth: 🟢 48.3% YoY
This represents one of the fastest-growing components of Lupin's geographic portfolio during the quarter.
Emerging Markets Record The Fastest Growth
Emerging Markets recorded revenue of ₹990 crore, representing an impressive:
Among the geographic segments provided, this represents the highest year-on-year growth rate.
The strong performance across both developed and emerging international markets indicates that Lupin's growth in the quarter was geographically broad-based.
▲ 51.7% YoY
Among the geographic segments provided, this represents the highest year-on-year growth rate.
The strong performance across both developed and emerging international markets indicates that Lupin's growth in the quarter was geographically broad-based.
Lupin Segment-Wise Q1 FY27 Performance
| Business | Revenue | YoY Growth |
| U.S. | ₹3,435 Cr | 🟢 +42.9% |
| India | ₹2,380 Cr | 🟢 +13.9% |
| Other Developed Markets | ₹1,149 Cr | 🟢 +48.3% |
| Emerging Markets | ₹990 Cr | 🟢 +51.7% |
| API | ₹264 Cr | 🟢 +8.5% |
Formulations Remain The Core Of Lupin's Business
Total formulations revenue increased to ₹7,954 crore, representing growth of 34.3% YoY.
Total product sales, meanwhile, increased to ₹8,217 crore, up 33.3% YoY.
TOTAL FORMULATIONS REVENUE
₹7,954 Cr
🟢 +34.3% YoY
TOTAL PRODUCT SALES
₹8,217 Cr
🟢 +33.3% YoY
₹7,954 Cr
🟢 +34.3% YoY
TOTAL PRODUCT SALES
₹8,217 Cr
🟢 +33.3% YoY
The scale and growth of formulations revenue reinforce the importance of Lupin's core pharmaceutical product portfolio to the overall quarterly performance.
What Are The Biggest Positives From Lupin's Results?
✓ Revenue increased 32% YoY
✓ EBITDA surged 42% YoY
✓ Net profit increased 16% YoY
✓ EBITDA margin expanded approximately 200 bps YoY
✓ U.S. revenue increased 42.9% YoY
✓ Other Developed Markets grew 48.3% YoY
✓ Emerging Markets grew 51.7% YoY
✓ India business maintained 13.9% YoY growth
✓ Formulations revenue increased 34.3% YoY
The breadth of growth across major geographic markets is arguably one of the strongest aspects of the quarter.
✓ EBITDA surged 42% YoY
✓ Net profit increased 16% YoY
✓ EBITDA margin expanded approximately 200 bps YoY
✓ U.S. revenue increased 42.9% YoY
✓ Other Developed Markets grew 48.3% YoY
✓ Emerging Markets grew 51.7% YoY
✓ India business maintained 13.9% YoY growth
✓ Formulations revenue increased 34.3% YoY
The breadth of growth across major geographic markets is arguably one of the strongest aspects of the quarter.
What Are The Main Concerns?
Despite strong YoY numbers, investors should not ignore the sequential performance.
⚠ EBITDA margin fell from 33.2% to 29.6% QoQ
⚠ EBITDA declined 1% QoQ despite revenue increasing 11%
⚠ Net profit declined 4% QoQ
The key question is whether the sequential margin contraction represents a temporary normalisation or develops into a broader trend.
The supplied data alone does not answer that question, making subsequent quarters and management commentary important monitorables.
⚠ EBITDA margin fell from 33.2% to 29.6% QoQ
⚠ EBITDA declined 1% QoQ despite revenue increasing 11%
⚠ Net profit declined 4% QoQ
The key question is whether the sequential margin contraction represents a temporary normalisation or develops into a broader trend.
The supplied data alone does not answer that question, making subsequent quarters and management commentary important monitorables.
What Should Investors Monitor Next?
1. U.S. Growth Sustainability
With the U.S. contributing 42% of total sales and growing 42.9% YoY, sustaining momentum in this market will be important.
2. EBITDA Margin
Whether margins stabilise around current levels or recover after the sequential decline from 33.2%.
3. Emerging Markets
Whether the exceptional 51.7% YoY growth can remain strong in subsequent quarters.
4. Developed Markets
Continuation of the 48.3% growth reported during Q1 would support geographic diversification.
5. India Business
The domestic franchise remains a significant contributor and continued double-digit growth would provide additional earnings stability.
6. PAT Growth
Investors should monitor whether strong revenue and EBITDA growth translate into faster bottom-line growth in subsequent quarters.
With the U.S. contributing 42% of total sales and growing 42.9% YoY, sustaining momentum in this market will be important.
2. EBITDA Margin
Whether margins stabilise around current levels or recover after the sequential decline from 33.2%.
3. Emerging Markets
Whether the exceptional 51.7% YoY growth can remain strong in subsequent quarters.
4. Developed Markets
Continuation of the 48.3% growth reported during Q1 would support geographic diversification.
5. India Business
The domestic franchise remains a significant contributor and continued double-digit growth would provide additional earnings stability.
6. PAT Growth
Investors should monitor whether strong revenue and EBITDA growth translate into faster bottom-line growth in subsequent quarters.
Lupin Q1 FY27 Earnings Scorecard
| Parameter | Assessment |
| Revenue Growth | 🟢 Strong |
| EBITDA Growth YoY | 🟢 Very Strong |
| Net Profit Growth YoY | 🟢 Positive |
| YoY Margin Trend | 🟢 Improving |
| QoQ Margin Trend | 🟡 Weakening |
| U.S. Business | 🟢 Strong |
| International Diversification | 🟢 Strong |
| Overall Q1 FY27 | 🟢 STRONG / POSITIVE |
Are Lupin's Q1 FY27 Results Strong?
LUPIN Q1 FY27 ASSESSMENT
🟢 STRONG / POSITIVE
🟢 STRONG / POSITIVE
Based strictly on the supplied Q1 FY27 numbers, Lupin delivered a strong quarter on a year-on-year basis.
The key evidence is compelling:
✓ 32% revenue growth
✓ 42% EBITDA growth
✓ 16% PAT growth
✓ 200-basis-point YoY EBITDA margin expansion
✓ 42.9% U.S. revenue growth
✓ 48.3% growth in Other Developed Markets
✓ 51.7% growth in Emerging Markets
The principal qualification is the 360-basis-point sequential contraction in EBITDA margin, accompanied by a small QoQ decline in EBITDA and PAT.
Therefore, the quarter appears fundamentally strong from the supplied data, while margin sustainability becomes an important monitorable.
Investor Takeaway
Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, who is also a SEBI Regd Investment Adviser, observes that Lupin's Q1 FY27 performance stands out because growth was not confined to a single metric or geography.Revenue grew strongly, EBITDA expanded considerably faster than revenue, and the U.S., Other Developed Markets and Emerging Markets all recorded substantial year-on-year growth.
The quarter can be summarised as:
REVENUE
🟢 +32% YoY
↓
EBITDA
🟢 +42% YoY
↓
EBITDA MARGIN
🟢 27.6% → 29.6% YoY
↓
NET PROFIT
🟢 +16% YoY
GLOBAL GROWTH
🟢 Broad-Based
🟢 +32% YoY
↓
EBITDA
🟢 +42% YoY
↓
EBITDA MARGIN
🟢 27.6% → 29.6% YoY
↓
NET PROFIT
🟢 +16% YoY
GLOBAL GROWTH
🟢 Broad-Based
However, investors should distinguish the excellent year-on-year performance from the softer sequential margin trend. Revenue rose 11% QoQ while EBITDA and PAT declined marginally and EBITDA margin contracted to 29.6%.
Consequently, the sustainability of margins alongside continued U.S. and international growth is likely to be one of the most important factors to monitor in coming quarters.
Based on the supplied financial data alone, Lupin's Q1 FY27 earnings deserve a Strong / Positive assessment.
Read Free content at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
Source Note: This analysis is based on the supplied Lupin Q1 FY27 consolidated results and segment-wise performance figures. No valuation, price target or management guidance has been assumed beyond the information supplied.
Written by Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
Disclaimer: This article is for educational and informational purposes only and should not be considered a recommendation to buy, sell or hold Lupin or any other security. Quarterly financial performance can fluctuate and should not be considered in isolation. Investors should independently examine detailed financial statements, business outlook, valuations, regulatory developments and their individual risk profile before making an investment decision.
Written by Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
Disclaimer: This article is for educational and informational purposes only and should not be considered a recommendation to buy, sell or hold Lupin or any other security. Quarterly financial performance can fluctuate and should not be considered in isolation. Investors should independently examine detailed financial statements, business outlook, valuations, regulatory developments and their individual risk profile before making an investment decision.
